Home › Carcinoma a cellule squamose della testa e del collo › Kentucky › Louisville
Studi clinici su Carcinoma a cellule squamose della testa e del collo a Louisville, KY
11 studi su Carcinoma a cellule squamose della testa e del collo cercano partecipanti presso sedi a Louisville e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
In reclutamentoFase 2/3
- Site#0111, Louisville
- Site#0115, Louisville
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
In reclutamentoFase 2
- The James Graham Brown Cancer Center at University of Louisville, Louisville
- UofL Health Medical Center Northeast, Louisville
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
In reclutamentoFase 1
- Norton Cancer Institute, Louisville
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
In reclutamentoFase 2
- The James Graham Brown Cancer Center at University of Louisville, Louisville
- UofL Health Medical Center Northeast, Louisville
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
In reclutamentoFase 2
- Norton Cancer Institute, Louisville
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
In reclutamentoFase 2
- Baptist Health Floyd, New Albany · a 4 mi di distanza
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
In reclutamentoFase 3
- The James Graham Brown Cancer Center at University of Louisville, Louisville
- UofL Health Medical Center Northeast, Louisville
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
In reclutamentoFase 1/2
- Norton Cancer Institute, Louisville
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
In reclutamentoFase 1/2
- Norton Cancer Institue Downtown, Louisville
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
In reclutamentoFase 1
- Norton Cancer Institute /ID# 248903, Louisville
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
In reclutamentoFase 1/2
- Research Site 115, Louisville
Studi su Carcinoma a cellule squamose della testa e del collo in altre città
- Houston, TX47 studi
- Los Angeles, CA42 studi
- Boston, MA40 studi
- Nashville, TN39 studi
- New York City, NY39 studi
- St. Louis, MO28 studi
- Arlington, VA26 studi
- Chicago, IL26 studi
- Philadelphia, PA26 studi
- Atlanta, GA24 studi
- San Antonio, TX22 studi
- Pittsburgh, PA22 studi
Altri studi a Louisville
- Cancro del polmone non a piccole cellule22 studi
- Obesità17 studi
- Sovrappeso15 studi
- Cancro (tutti i tipi)14 studi
- Insufficienza cardiaca13 studi
- Leucemia mieloide acuta12 studi
- Mieloma multiplo12 studi
- Cancro ovarico12 studi
- Cancro al seno11 studi
- Cancro ai polmoni11 studi
- Melanoma10 studi
- Cancro alla prostata10 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.